TXNDC5 protects synovial fibroblasts of rheumatoid arthritis from the detrimental effects of endoplasmic reticulum stress

Qiqi Lu1, Jinguang Wang2, Xiumei Zhang3, Ruisong Tian4, Li Qiao5, Luna Ge4, Jihong Pan4, Lin Wang4,*

1 School of Medicine and Life Sciences, University of Ji’nan-Shandong Academy of Medical Sciences, Ji’nan, Shandong, China; 2 Department of Orthopedics, Dezhou People's Hospital, Dezhou, Shandong, China; 3 Graduate Education Centre of the Shandong Academy of Medical Sciences, Ji’nan, Shandong, China; 4 Shandong Medicinal Biotechnology Centre, Key Laboratory for Rare and Uncommon Diseases of Shandong Province, Key Lab for Biotechnology Drugs of the Ministry of Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Ji’nan, Shandong, China; 5 College of Clinical Medicine, Shandong University, Ji’nan, Shandong, China.

SUMMARY TXNDC5 is an endoplasmic reticulum (ER)-resident chaperone that protects the endothelium from secondary effects of ER stress. Previous studies by the current authors identified TXNDC5 as a key pathological factor in promoting the inflammatory phenotype of fibroblast-like synoviocytes (FLSs) from rheumatoid arthritis (RA). However, its activity in RA FLSs under ER stress remains unclear. The current study found that TXNDC5 is responsive to ER stress in RA FLSs since its expression was induced by ER stress at both the endogenous and secretory level. A functional study indicated that silencing TXNDC5 reduced the viability of RA FLSs more markedly in the presence of ER stressors. In contrast, rhTXNDC5 attenuated a decrease in cell viability as a result of ER stress. Moreover, silencing TXNDC5 attenuated the induction of IL-6 and IL-8 from RA FLSs in response to ER stress. In addition, rhTXNDC5 induced a greater increase in VEGF production during ER stress. These findings confirm the pro-survival and pro-inflammation roles of TXNDC5 under ER stress in RA FLSs. TXNDC5 appears to act as a mediator linking ER stress and inflammation of RA.

Keywords TXNDC5, endoplasmic reticulum stress, rheumatoid arthritis

1. Introduction
Rheumatoid arthritis (RA) is an inflammatory joint disease characterized by hyperplasia of synovial tissue and formation of pannus (1,2). Excessive inflammatory molecules, such as cytokines and matrix metalloproteinase, are secreted and promote the destruction of cartilage and bone (3,4). Analyses of hyperplastic synovial tissue from patients with RA have revealed features of transformed long-living cells, such as the presence of somatic mutations, expression of oncogenes, and resistance to apoptosis (5). Therefore, identification of the components that are sensitive to the stimuli in the microenvironment of an inflamed joint is crucial to understanding the pathogenesis of RA and may also provide new targets for diagnosis and treatment (6,7).

Endoplasmic reticulum (ER) stress is a cellular danger signal, and diverse conditions including hypoxia and inflammation, which are frequently observed in joints affected by RA, can be considered inducers of ER stress (8). Fibroblast-like synoviocytes (FLSs) are predisposed to apoptotic resistance to ER stress and contribute to synovial hyperplasia of RA (9), but the mechanism of this pathology has yet to be fully clarified (10,11). Thioredoxin domain-containing protein 5 (TXNDC5) is a protein-disulfide isomerase located in the ER that functions as a chaperone. In vitro and in vivo studies by the current authors found that TXNDC5 was closely related to the pathological progression of RA and prostate cancer (12,13). Recently, the current authors found that TXNDC5 coordinated with HSC70 to exacerbate the inflammatory phenotype of RA at the endogenous level (14). More importantly, previous findings indicated that TXNDC5 is responsive to extracellular stimuli, such as hypoxia, pro-inflammatory factors, and androgen-deprivation, indicating that TXNDC5 may be required to adapt to extracellular changes in an inflamed joint (15). In addition, TXNDC5 expression was detected in synovial fluid from patients with RA, and its exact function in soluble form remains
unclear (16). Intriguingly, a previous study found that TXNDC5 protects endothelial cells from stress-induced cell death. However, the exact role of TXNDC5 under ER stress remains unclear (17).

The current study examined whether TXNDC5 expression is up-regulated when stimulated with an inducer of ER stress. TXNDC5 was knocked down to make the inhibitory effects of ER stress on the cell viability of RA FLSs more apparent, and RA FLSs were treated with recombinant human TXNDC5 (rhTXNDC5) to determine if those effects were attenuated. In addition, the expression of inflammatory factors, such as IL-6 and IL-8, was measured in response to rhTXNDC5 treatment plus ER stress. TXNDC5 was silenced to determine the response to an inducer of ER stress. This study examined whether TXNDC5 is sensitive to ER stress in RA FLSs and whether it functions as a link between ER stress and inflammation in RA.

2. Materials and Methods

2.1. Patients

Subjects were 12 patients with RA who had undergone knee joint replacement surgery. All of the patients fulfilled the 1987 American College of Rheumatology revised criteria for the diagnosis of RA. Written informed consent was obtained from every patient, and all samples were anonymized.

2.2. Stimulation assays

Primary RA FLSs were isolated and cultured as described previously (4), and cells passaged 3-7 times were used in this study. For stimulation, RA FLSs were plated on 24-well plates (3-5 × 10^5 cells/well) in Dulbecco's modified Eagle's medium and stimulated for the indicated times with the following agents: recombinant human TXNDC5, thapsigargin, tunicamycin, LPS, and a hypoxia inducer (CoCl2).

2.3. Small interfering RNA transfection in RA FLSs

RA FLSs (2 × 10^5 cells in 100-mm-diameter dishes or 8 × 10^5 cells on 6-well plates) were transiently transfected with siRNA targeting TXNDC5 (#1:S100132440; #2: S100132447, QIAGEN, Hilden, Germany) or a negative control (QIAGEN, S103650318) with a Hiperfect transfection reagent (QIAGEN) in accordance with the manufacturer's instructions, and all experiments were performed 24-48 h after transfection. Non-specific negative control siRNAs were also designed and synthesized (sense strand: 5’-UUUCUCCGAACGUGUCACG-3’ and anti-sense strand: 5’-ACGUGACACGUGUCAGAATT-3’). Two siRNAs targeting the same gene were mixed together in equal volumes to verify the reliability of silencing efficiency and were designated siTXNDC5.

2.4. Cell viability

Briefly, 1 × 10^4 cells were seeded onto each well of 96-well plates for the indicated treatment. On the day of detection, 20 μL MTS (Promega) was added to each well. After incubation for 1 h at 37°C, the plates were shaken at room temperature for 10 min. The absorbance was measured at 495 nm, and three independent experiments were analyzed.

2.5. ELISA

Cells were cultured and stimulated as described above, and supernatants were collected as the indicated timepoints. After centrifugation to remove particulates, the release of VEGF (R&D Systems) was analyzed with ELISA in accordance with the manufacturer's instructions.

2.6. RNA extraction and real time RT-PCR (qRT-PCR)

RNA extraction and qRT-PCR were performed as previously described (18). Details on the primers are shown in Supplementary Table 1 (http://www.irdrjournal.com/action/getSupplementalData.php?ID=54). GAPDH was used as internal loading control. Relative mRNA levels were measured using the 2-Δ cycle threshold (2-ΔCT) method. Three independent experiments were completed, and each reaction was performed in triplicate.

2.7. Measurement of apoptosis using flow cytometry

Apoptosis was also assessed with Annexin V-APC/7-amino-actinomycin D staining (KeyGEN, Nanjing, China). Briefly, cells were harvested, washed with phosphate-buffered saline, resuspended in 500 μL of binding buffer, mixed with 5 μl of Annexin V-APC and 5μl of 7-ADD, and incubated for 5-15 min in the dark. Fifty thousand cells were analyzed using a FACSCalibur cytometer. Annexin V-positive cells were considered apoptotic cells and analyzed using the software ModFit. The assays were carried out in triplicate in three experiments.

2.8. Statistical analyses

Data were statistically analyzed using the software SPSS V.16 (SPSS). The t test was used to assess statistical differences between two groups. A P value < 0.05 was considered significant. Data are expressed as the mean ± standard deviation.

3. Results

3.1. TXNDC5 is responsive to ER stress in RA
ER chaperones regulate cell survival, and TXNDC5 has been reported to protect endothelial cells from cell death induced by stress (19). However, the role of TXNDC5 in RA FLS survival under ER stress is not known. As shown in Figure 2A, tunicamycin and thapsigargin significantly increased the number of TUNEL-positive apoptotic cells among RA FLSs when TXNDC5 siRNA was introduced, in comparison to the control. Moreover, TXNDC5 siRNA-transfected cells had a more marked decrease in cell viability when treated with tunicamycin and thapsigargin (Figure 2B). These findings suggest that TXNDC5 played an important role in maintaining the survival of RA FLSs in response to proapoptotic ER stress in joints affected by RA.

3.3. Exogenous TXNDC5 protects cells from ER stress

A study has indicated that protein secreted in response to ER stress may in turn protect against ER stress-induced apoptosis (20). The current study investigated whether TXNDC5 in this soluble form had a similar effect on RA FLSs. Recombinant human TXNDC5 (rhTXNDC5) was used to mimic its extracellular form, and experimental doses of rhTXNDC5 used had no
cytotoxic effect on RA FLSs (results not shown). As expected, the number of TUNEL-positive apoptotic RA FLSs induced by tunicamycin and thapsigargin decreased significantly in a dose-dependent manner when RA FLSs were preincubated with rhTXNDC5 (Figure 2C). The effect of rhTXNDC5 on cell viability following ER stress was analyzed using the MTS assay. rhTXNDC5- and vehicle-treated cells were seeded and cultured for 6 h prior to addition of tunicamycin and thapsigargin for 24, 48 and 72 h. Cell viability at each time point was evaluated using the MTS assay and normalized to the respective cell type without ER stress. As shown in Figure 2D, the number of viable rhTXNDC5-treated cells was greater than the number of control cells at all time points as a result of treatment with tunicamycin at a certain concentration (5 ug/mL). The number of cells differed significantly. Similar results were obtained when cells were treated with thapsigargin (50 nM, Figure 2D). Hence, rhTXNDC5-treated cells clearly have increased resistance to ER stress.

3.4. TXNDC5 facilitates cytokine expression and angiogenesis under ER stress

A previous study by the current authors found that cytokine production in response to pro-inflammatory stimuli was attenuated by silencing endogenous TXNDC5. A study has reported that tunicamycin can also induce cytokine production (21), so the current study investigated the effect of TXNDC5 on ER-stress mediated cytokine production by RA FLSs. Consistent with results of the previous study, levels of IL6 and IL-8 increased after stimulation with tunicamycin. However, silencing endogenous TXNDC5 suppressed the induction of cytokine expression in response to ER stress (Figure 3A and 3B).

The effect of rhTXNDC5 on cytokine expression in RA FLSs was examined. A qRT-PCR assay indicated that addition of rhTXNDC5 did not significantly induce the expression of IL-6 and IL-8 by RA FLSs. More interestingly, rhTXNDC5 plus LPS (Figure 3C and 3D) or hypoxia (Figure 3E and 3F) additively increased cytokine expression in a time- and concentration-dependent manner. These results indicate that TXNDC5 may act as a mediator to exacerbate inflammation under ER stress. An attempt was made to determine whether TXNDC5 affects the angiogenic process. Interestingly, the current findings indicated that rhTXNDC5 treatment induced VEGF production in RA FLSs in response to tunicamycin (Figure 3G) and thapsigargin (Figure 3H).

4. Discussion

As a stress protein residing mainly in the ER, TXNDC5 is induced under ER stress and is involved in the regulation of ER homeostasis (22). RA is characterized by genes involved in ER stress (23,24). However, the relative contribution of TXNDC5 to RA in response to ER stress remains unclear. RA FLSs are exposed to diverse conditions including hypoxia and pro-inflammatory cytokines, and these factors act as ER stressors to exacerbate inflammation as well (25). A point worth noting is that previous findings indicated that TXNDC5 in RA FLSs is sensitive to proinflammatory cytokines (IL-1, TNF-α, or IL-6) and hypoxia, increasing the likelihood that TXNDC5 may be functional in RA when ER stress occurs. The current study characterized the expression of TXNDC5 in RA under ER stress, and results further confirmed that TXNDC5 expression both in the cytoplasm and
supernatant of RA FLSs is sensitive to an inducer of ER stress, such as thapsigargin and tunicamycin. Recently, the current authors found that silencing TXNDC5 attenuated the induction of IL6 and IL8 in the presence of proinflammatory factors, such as LPS and TNF-α (14). The current study provides evidence that silencing TXNDC5 in RA FLSs suppresses the stimulatory effects of ER stressors on inflammatory factors. These findings clearly corroborate TXNDC5’s involvement in promoting inflammation under ER stress in RA.

A previous study indicated that TXNDC5 protects endothelial cells from stress-induced apoptosis (17). Similar effects were also observed in RA FLSs as evinced by both cell viability and inflammatory factor expression. TXNDC5 expression is higher in RA FLSs than in osteoarthritis (OA) FLSs (12), so the aforementioned finding may also explain why RA FLSs were more resistant to apoptosis than OA FLSs. Indeed, a growing body of evidence suggests that the signaling pathways in ER stress and inflammation are interconnected through various mechanisms, including the production of reactive oxygen species (ROS) (26), the release of calcium from the ER (27), the activation of nuclear transcription factor NF-κB and the mitogen-activated protein kinase (MAPK) known as JUN N-terminal kinase (JNK) (28), and the induction of the acute-phase response. A previous study by the current authors indicated that TXNDC5 directly interacts with heat shock cognate 70 protein (HSC70) to sequester it in the cytoplasm and that HSC70 activates NF-κB signaling by destabilizing IκBβ protein (14). Importantly, RA has been found to respond to TXNDC5 secretion by activating multiple inflammatory pathways and triggering the production of proinflammatory cytokines, suggesting that TXNDC5 is an important component of the micro-environment to mediate the pathological progression of RA. TXNDC5 may act as a mediator linking ER stress and the inflammatory response.

RA is the main source of many angiogenic factors, including VEGF, in the joints, and the level of VEGF has been proven to be highly correlated with RA disease activity (29). VEGF signaling is activated in response to ER stress, and activated VEGF signaling, in turn, buffers the levels of ER stress (30). A previous study by the current authors indicated that silencing TXNDC5 suppressed VEGF production in RA FLSs when stimulated with LPS and TNF-α. The current study...
provides further evidence that rhTXNDC5 induces VEGF production during ER stress. These findings suggest that TXNDC5 may mediate angiogenesis under ER stress, and they also corroborate the close relationship between ER stress and angiogenesis during the progression of RA.

In summary, this study found that an increase in TXNDC5 as a cytoprotective response to ER stress may link ER stress and inflammation in RA. Specifically targeting TXNDC5 may be a potential treatment for RA.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (grant nos. 81572544 and 81772760), the Shandong Taishan Scholarship (grant no. tsqn20161076), The Innovation Project of the Shandong Academy of Medical Sciences and the Youth Innovation Technology Plan of Shandong University (2019KJK003).

References

1. Kuo WS, Weng CT, Chen JH, Wu CL, Shiau AL, Hsieh JL, So EC, Wu PT, Chen SY. Amelioration of experimentally induced arthritis by reducing reactive oxygen species production through the intra-articular injection of water-soluble fullerenol. Nanomaterials (Basel). 2019; 9:909.

2. You S, Koh JH, Leng L, Kim Wu, Bucala R. The tumor-like phenotype of rheumatoid synovium: Molecular profiling and prospects for precision medicine. Arthritis Rheumatol. 2018; 70:637-652.

3. Rana AK, Li Y, Dang Q, Yang F. Monocytes in rheumatoid arthritis: Circulating precursors of macrophages and osteoclasts and, their heterogeneity and plasticity role in RA pathogenesis. Int Immunopharmacol. 2018; 65:348-359.

4. Wang L, Song G, Zheng Y, Wang D, Dong H, Pan J, Chang X. miR-573 is a negative regulator in the pathogenesis of rheumatoid arthritis. Cell Mol Immunol. 2016; 13: 839-849.

5. Simon TA, Boers M, Hochberg M, Baker N, Skovron ML, Ray N, Singhal S, Suissa S, Gomez-Camino. A. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: A multi-database real-world study. Arthritis Res Ther. 2019; 21:222.

6. Carrióñ M, Frommer KW, Pérez-Garcíaa S, Müller-Ladner U, Gomariz RP, Neumann E. The adipokine network in rheumatic joint diseases. Int J Mol Sci. 2019; 20:4091.

7. Asif Amin M, Fox DA, Ruth JH. Synovial cellular and molecular markers in rheumatoid arthritis. Semin Immunopathol. 2017; 39:385-393.

8. Rahmati M, Moosavi MA, McDermott MF. ER stress: A therapeutic target in rheumatoid arthritis? Trends Pharmacol Sci. 2018; 39:610-623.

9. Kurowska M, Rudnicka W, Kontny E, Janicka I, Chorazy M, Kowalczewski J, Ziółkowska M, Ferrari-Lacraz S, Strom TB, Maśliński W. Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: Endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-x(L) and Bcl-2. J Immunol. 2002; 169:1760-1767.

10. Shin YJ, Han SH, Kim DS, Lee GH, Yoo WH, Kang YM, Choi JY, Lee YC, Park SJ, Jeong SK, Kim HT, Chae SW, Jeong HJ, Kim HR, Chae HJ. Autophagy induction and CHOP under-expression promotes survival of fibroblasts from rheumatoid arthritis patients under endoplasmic reticulum stress. Arthritis Res Ther. 2010; 12:19.

11. Gao B, Lee SM, Chen A, Zhang J, Zhang DD, Kannan K, Ortmann RA, Fang D. Synoviolin promotes IRE1 ubiquitination and degradation in synovial fibroblasts from mice with collagen-induced arthritis. EMBO Rep. 2008; 9:480-485.

12. Chang X, Zhao Y, Yan X, Pan J, Fang K, Wang L. Investigating a pathogenic role for TXNDC5 in rheumatoid arthritis. Arthritis Res Ther. 2011; 13:124.

13. Chang X, Xu B, Wang L, Wang Y, Wang Y, Yan S. Investigating a pathogenic role for TXNDC5 in tumors. Int J Oncol. 2013; 43:1871-84.

14. Wang L, Dong H, Song G, Zhang R, Pan J, Han J. TXNDC5 synergizes with HSC70 to exacerbate the inflammatory phenotype of synovial fibroblasts in rheumatoid arthritis through NF-κB signaling. Cell Mol Immunol. 2018; 15:685-696.

15. Wang L, Song G, Chang X, Tan W, Pan J, Zhu X, Liu Z, Qi M, Yu J, Han B. The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway. Oncogene. 2015; 34:4735-4745.

16. Chang X, Cui Y, Zong M, Zhao Y, Yan X, Chen Y, Han J. Identification of proteins with increased expression in rheumatoid arthritis synovial tissues. J Rheumatol. 2009; 36:872-880.

17. Chawsheen HA, Jiang H, Ying Q, Ding N, Thapa P, Wei Q. The redox regulator sulfiredoxin forms a complex with thioredoxin domain-containing 5 protein in response to ER stress in lung cancer cells. J Biol Chem. 2019; 294:8991-9006.

18. Wang L, Song G, Zheng Y, Tan W, Pan J, Zhao Y, Chang X. Expression of Semaphorin 4A and its potential role in rheumatoid arthritis. Arthritis Res Ther. 2015; 17:227.

19. Xu B, Li J, Liu X, Li C, Chang X. TXNDC5 is a cervical tumor susceptibility gene that stimulates cell migration, vasculoegenic mimicry and angiogenesis by down-regulating SFRPIN1 and TRAF1 expression. Oncotarget. 2017; 8:91009-91024.

20. Li M, Liu Y, Xia F, Wu Z, Deng L, Jiang R, Guo FJ. Proteinulin is required for proper ER stress response and inhibits ER stress-mediated apoptosis through TNFR2. Cell Signal. 2014; 26:1539-1548.

21. Zhang L, Pavicic PG Jr, Dutta S, Song Q, Xu X, Wei W, Su F, Rayman PA, Zhao C, Hamilton T. Unfolded protein response differentially regulates TLR4-induced cytokine expression in distinct macrophage populations. Front Immunol. 2019; 10:1390.

22. Chawsheen HA, Ying Q, Jiang H, Wei Q. A critical role of the thioredoxin domain containing protein 5 (TXNDC5) in redox homeostasis and cancer development. Genes Dis. 2018; 5:312-322.

23. Marinou I, Walters K, Dickson MC, Binks MH, Bax DE, Wilson AG. Evidence of epistasis between interleukin 1 and selenoprotein-S with susceptibility to rheumatoid arthritis. Ann Rheum Dis. 2009; 68:1494-1497.
24. Yoo SA, You S, Yoon HJ, Kim DH, Kim HS, Lee K, Ahn JH, Hwang D, Lee AS, Kim KJ, Park YJ, Cho CS, Kim WU. A novel pathogenic role of the ER chaperone GRP78/BiP in rheumatoid arthritis. J Exp Med. 2012; 209:871-886.

25. Veale DJ, Orr C, Fearon U. Cellular and molecular perspectives in rheumatoid arthritis. Semin Immunopathol. 2017; 39:343-354.

26. Lin Y, Jiang M, Chen W, Zhao T, Wei Y. Cancer and ER stress: Mutual crosstalk between autophagy, oxidative stress and inflammatory response. Biomed Pharmacother. 2019; 118:109249.

27. Barrera MJ, Aguilera S, Castro I, González S, Carvajal P, Molina C, Hermoso MA, González MJ. Endoplasmic reticulum stress in autoimmune diseases: Can altered protein quality control and/or unfolded protein response contribute to autoimmunity? A critical review on Sjögren's Syndrome. Autoimmun Rev. 2018; 17:796-808.

28. Ochoa CD, Wu RF, Terada LS. ROS signaling and ER stress in cardiovascular disease. Mol Aspects Med. 2018; 63:18-29.

29. Strunk J, Rumbaur C, Albrecht K, Neumann E, Müller-Ladner U. Linking systemic angiogenic factors (VEGF, angiogenin, TIMP-2) and Doppler ultrasound to anti-inflammatory treatment in rheumatoid arthritis. Joint Bone Spine. 2013; 80:270-273.

30. Binet F, Sapieha P. ER stress and angiogenesis. Cell Metab. 2015; 22:560-575.

Received December 21, 2019; Revised January 30, 2020; Accepted February 4, 2020.

*Address correspondence to:
Lin Wang, Shandong Medicinal Biotechnology Centre, Key Laboratory for Rare and Uncommon Diseases of Shandong Province, Key Lab for Biotechnology Drugs of Ministry of Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250062, China.
E-mail: wanglin.83@163.com

Released online in J-STAGE as advance publication February 16, 2020.